the engineering of strains of mice to produce human instead of mouse antibodies, has been emerging and evolving for the past two decades. Now, with the 2006 US regulatory approval of panitumumab, a fully human antibody directed against the epidermal growth factor receptor, transgenic mice expressing human antibody repertoires join chimerization, CDR grafting, and phage display technologies, as a commercially validated antibody drug discovery platform. With dozens of additional transgenic mouse-derived human MAbs now in clinical development, this new drug discovery platform appears to be firmly established within the pharmaceutical industry.
Immunogenicity of Therapeutic Antibodies: Problem and Solutions
The discovery of hybridoma methods in 1975 for isolating high specificity and high affinity rodent monoclonal antibodies (MAbs) opened the door to a new class of therapeutic compounds with potential applicability across a wide range of disease indications (Kohler and Milstein 1975) . This promise appeared to be fulfilled with the 1986 US regulatory approval of muromonab-CD3 for the treatment of kidney transplant rejection (Goldstein et al. 1985) . However, despite the fact that muromonomab-CD3 acts as a potent immunosuppressive drug, it turned out to be an intrinsically immunogenic molecule. Because rodent antibodies are foreign proteins, the human immune system mounts its own antibody response to them, leading to rapid clearance, reduced efficacy (Goldstein et al. 1985; Pendley et al. 2003; Kuus-Reichel et al. 1994) , and an increased risk of infusion reactions (Baert et al. 2003) . A potential solution to the problem of immunogenicity, fully human MAbs, did not at the time appear to be practical because of the limited availability of target specific human antibodies (Larrick and Bourla 1986; James and Bell 1987; Houghton 1983; Olsson et al. 1984) . Although very large panels of rodent MAbs could be easily assembled and screened for optimal binding to the intended target and low cross-reactivity to related molecules, analogous technologies for generating and isolating human MAbs with the full range of specificities and affinities afforded by rodent hybridoma methods did not exist. The smaller pools of available reactive human antibodies might have been a factor in the selection of early human MAb clinical candidates such as HA-1A, which entered clinical testing for treatment of sepsis in the late 1980s and gained European regulatory approval in 1991 (Brun-Buisson 1994) . This polyreactive authentic human MAb bound to its intended target, lipid A, through relatively nonspecific hydrophobic interactions of heavy chain V region framework residues (Helmhorst et al. 1998; Bieber et al. 1995) . The 1992 clinical, and US regulatory, failure of HA-1A (Spalding 1992; Edgington 1992; McCloskey et al. 1994) , together with the observed immunogenicity of muromonomab-CD3, contributed to a considerable cooling of enthusiasm for antibody-based drugs within the pharmaceutical industry. However, 8 years after the approval of muromonomab-CD3, a second MAb-based drug, the engineered chimeric antibody fragment abciximab (Simoons et al. 1994) , gained approval. This was followed by the approval of 18 additional MAb-based drugs in the last 10 years. As a class of drug compounds, MAbs appear to have been rescued by the use of technologies for reengineering rodent antibodies in vitro to replace framework amino acid residues with corresponding human sequences (Morrison et al. 1984; Jones et al. 1986 ). Additional technologies were also developed to directly isolate synthetic MAbs from libraries of human and synthetic immunoglobulin sequences (McCafferty 1990) . Although these existing antibody engineering technologies appear to have been very successful in generating therapeutic products with acceptable safety and efficacy, there may still be room for improvement. Although some of the products generated by antibody engineering have not elicited patient immune responses, most of the approved MAb products, including examples from chimerization, CDR grafting and phage display, have been found to be immunogenic (Pendley et al. 2003) .
Fig. 1
Evolution of therapeutic antibody technology and progress to the clinic. FDA-approved MAbs have emerged between 10 and 12 years after the date that the new technologies on which they were based were reported in the scientific literature (Morrison et al. 1984; Jones et al. 1986; McCafferty et al. 1990; Kohler and Milstein 1975; Lonberg et al. 1994; Green et al. 1994) Transgenic mouse strains comprising human immunoglobulin repertoires represent an alternative platform technology for discovering low immunogenicity therapeutic MAbs (Fig. 1) . In contrast to antibody engineering technologies, which involve the downstream modification and optimization of individual protein molecules, transgenic technology is used for the upstream genetic engineering of strains of mice that are then used as drug discovery tools to directly generate human sequence antibodies that can be moved into the clinic without further optimization. Twelve years after their appearance in the scientific literature (Lonberg et al. 1994 , Green et al. 1994 , immunoglobulin transgenic mice have now been validated as drug discovery platforms by the regulatory approval of their first product, panitumumab (Gibson et al. 2006) . In this review, I discuss the development of the technology and drugs derived from it.
Development of Techniques for Manipulation of the Mouse Genome

Pronuclear Microinjection
Fundamental basic research in mouse embryology and molecular biology by a large number of laboratories (Nagy et al. 2003) led to the development, in the early 1980s, of a set of tools for the manipulation of the mouse genome (Fig. 2) . The generation of genetically engineered mice by direct microinjection of cloned DNA sequences into the pronuclei of single-cell half-day embryos was reported by several groups in 1981 (Gordon and Ruddle 1981; Costantini and Lacy 1981; Brinster et al. 1981; Harbers et al. 1981; Wagner et al. 1981a Wagner et al. , 1981b . The microinjected DNA constructs, which are inserted into mouse chromosomes and are propagated through the germline, could include transcriptional regulatory sequences to direct expression to restricted differentiated cell types, including B cell expression of antibody genes (Brinster et al. 1983 ). This first report of an expressed immunoglobulin gene in transgenic mice involved a very small transgene; however, despite the fact that very fine glass needles are employed for pronuclear microinjection, the sheer forces experienced by the injected DNA do not prevent the use of this technique for introducing much larger (>100 kb) transgenes into the mouse germline. (Costantini and Lacy 1981; Taylor et al. 1992; Schedl et al. 1993; Lonberg and Huszar 1995; Fishwild et al. 1996) .
Embryonic Stem Cells
Because microinjected transgenes integrate relatively randomly over a large number of potential sites within the mouse genome, it does not provide for easy manipulation of specific endogenous mouse genes. Microinjection could generate mice .5-day blastocyst stage embryos can be grown in culture, genetically modified, and then reintroduced into developing blastocysts by insertion of a glass pipet into the blastocoel cavity. (D) Site-specific modifications of ES cell genomes can be engineered through homologous recombination followed by selection and screening for specific recombinants in culture. (E) Large DNA fragments can be inserted into ES cell chromosomes by transfection or yeast/bacterial cell fusion. (F) Entire chromosomes or chromosome fragments, which replicate without integration into endogenous mouse chromosomes, can be introduced into ES cells by microcell-mediated chromosome transfer (MMCT). (G) The very short (ca. 2-3 months) generation time of the mouse allows for rapid crossbreeding to combine multiple independent genetic modifications into a single animal that expressed human genes, but the mouse ortholog was typically still active. This technical hurdle was overcome with the development of positive-negative selection vectors that allowed for the selection and screening of specifically targeted homologous recombination events in cultured cells, and with the parallel development of embryonic stem (ES) cell lines that could be cultured and manipulated in vitro and reintroduced into 3.5-day old blastocyst stage embryos to populate the germline of the resulting chimeric mice. The combination of these two technologies led to the generation of strains of engineered mice comprising specifically targeted modifications of their germlines (Mansour et al. 1988; Zijlstra et al. 1989; Schwartzberg et al. 1989) . The most commonly introduced specific modification leads to the inactivation of an endogenous gene and the creation of what are commonly referred to as gene knockout mouse strains. Gene knockout technology has proved to be of enormous value for basic research, and applied to the endogenous mouse immunoglobulin loci, important for the development of transgenic mouse platforms for human antibody drug discovery. In addition to applications for modifying endogenous mouse genes, ES cells have also proved useful as an alternative to pronuclear microinjection for the introduction of large DNA clones such as YAC clones (Strauss et al. 1993; Choi et al. 1993; Jakobovits et al. 1993; Davies et al. 1993) . Very large human chromosome fragments have also been introduced into the mouse germline using ES cell technology. In this approach, called microcell-mediated chromosome transfer (MMCT), human fibroblast-derived microcells are fused with mouse ES cells resulting in pluripotent cell lines having a single human chromosome or chromosome fragment -including a centromere and both telomeres -that replicates and assorts during cell division without insertion into an endogenous mouse chromosome (Tomizuka et al. 1997) .
Transgenic Mice with Human Immunoglobulin Genes
Expression of Human Antibody Repertoires
It was quickly recognized that the new tools developed for manipulating the mouse germline might be practically applied toward the generation of human immunoglobulin expressing transgenic mice. In 1985, Alt et al. (1985) suggested that transgenic technology could be useful for generating new human sequence MAbs starting from unrearranged, germline-configuration transgenes. The authors concluded that although this was "conceptually outlandish," it might "be realized in the not-toodistant future." A year later, Yamamura et al. (1986) reported the cell type specific expression of a human immunoglobulin gamma heavy chain transgene. This was followed by reports of expression and rearrangement of germline configuration (unrearranged) chicken and rabbit light chain transgenes in transgenic mice (Bucchini et al. 1987 , Goodhardt et al. 1987 ), a milestone that was recognized at the time as contributing toward the development of a transgenic platform for discovering human MAbs. Buttin (1987) commented that "recent progress in this field invites us to believe that the creation of transgenic mice with B cells secreting a wide spectrum of [human] antibodies is no longer out of reach. , Bruggemann et al. (1989 reported the expression of a repertoire of human IgM heavy chains and the generation of a transgene-encoded immune response in mice. Three years later, Taylor et al. (1992) reported mice comprising germline configuration human heavy-and κ light-chain transgenes that produced a repertoire of human IgM and IgG antibodies. This group showed in a later paper ) that the IgG antibodies were a product of class switching, and that they comprised somatic mutations consistent with functional affinity maturation. These reports, and many others from a number of different laboratories, demonstrated that human gene sequences could direct cell type specific expression of human immunoglobulins in mice, and that those exogenous gene sequences could undergo the normal rearrangements and modifications required for generating primary and secondary antibody repertoires. However, human immunoglobulin transgenic mice with intact functional endogenous immunoglobulin loci also express mouse antibodies and chimeric mousehuman antibodies. Creation of a more useful platform for human antibody drug discovery, a mouse with disrupted endogenous immunoglobulin loci, requires combining methods for introducing human immunoglobulin transgenes with the methods described earlier for generating gene knockout mice.
Transgenic Mouse Platforms for Therapeutic MAb Drug Discovery
In 1994, two articles, one from my laboratory (Lonberg et al. 1994 ) and the other from Green et al. (1994) , reported the generation of mice with four different germline modifications: two targeted disruptions (the endogenous mouse heavyand κ light-chain genes) and two introduced human transgenes (encoding the heavy chain and κ light chain). Although both articles report the use of homologous recombination in mouse ES cells to engineer similar disruptions of the endogenous mouse loci, different technologies were used to construct and deliver the human sequence transgenes. Lonberg et al. (1994) used pronuclear microinjection to introduce reconstructed minilocus transgenes -the heavy chain containing 3 heavy-chain variable (V H ), 16 diversity (D), and all 6 heavy-chain joining (J H ) regions together with µ and γ1 constant-region gene segments. In the transgenic strains, this construct underwent VDJ joining, together with somatic mutation and correlated class switching ). The light-chain transgene included four Vκ, all five Jκ and the κ constant region (Cκ). In contrast, Green et al. (1994) used fusion of yeast protoplasts to deliver yeast artificial chromosome (YAC)-based minilocus transgenes. In this case, the heavy chain included 5 V H , all 25 D and all 6 J H gene segments together with µ and δ constant-region gene segments. This construct underwent VDJ joining and expressed both IgM and IgD. The light-chain YAC construct included two functional Vκ and all five Jκ segments, together with Cκ. Neither group inactivated the endogenous λ-light-chain locus, which in typical laboratory mouse strains contributes to only ∼5% of the B cell repertoire. Functional λ-light-chain expression leads to a subpopulation of B cells producing hybrid B cell receptors and secreted antibodies that have human heavy-and mouse λ-light chains. However, the presence of this subpopulation did not prevent the isolation of hybridoma cell lines secreting fully human monoclonal IgM (Green et al. 1994) and IgG (Lonberg et al. 1994) MAbs recognizing the target antigens against which the mice had been immunized. The ability of these engineered mouse strains, each comprising only a fraction of the natural human primary V gene segment repertoire, to generate antibodies to a variety of targets may reflect the relative importance of combinatorial diversity (encoded in the germline library of V, D, and J gene segments) and junctional and somatic diversity (a product of the assembly and maturation of antibody genes).
Although naive B cell CDR1 and CDR2 sequences are completely encoded by the germ line, junctional diversity, which is intact in minilocus transgenes, creates much of the heavy-chain CDR3 repertoire. CDR3 sequences appear to be critical for antigen recognition by unmutated B cell receptors and may be largely responsible for the primary repertoire (Ignatovitch et al. 1997; Davis 2004; Tomlinson et al. 1996) . Primary repertoire B cells having low affinity for the immunogen can then enter into the T cell-mediated process of affinity maturation, which has been shown to generate high-affinity antibodies from a very limited V-gene repertoire. An extreme example of this is offered by a report of an engineered mouse strain having only a single functional human V H gene and three mouse Vλ genes (Xu and Davis 2000) . These animals demonstrated a specific antibody responses to a variety of T-dependent antigens. High affinity, somatically mutated MAbs were characterized, including a very high, 25 pM, affinity MAb against hen egg-white lysozyme. However, the minimal V-repertoire mice did not respond to the T-independent antigen, dextran B512, and the authors suggested that responses to carbohydrate antigens might drive evolutionary selection for large primary repertoires. Germline-encoded recognition of such antigens may be important for developing a rapid primary protective response to pathogens, a feature that would be selected for in the wild, but less important for isolating high-affinity antibodies from laboratory mice using hyperimmunization protocols that trigger T cell-dependent affinity maturation.
In addition to affecting the response to T-independent antigens and the kinetics of overall immune reactions, repertoire size may have an impact on B cell development and the size of different B cell compartments. Fishwild et al. (1996) compared mice having different numbers of light-chain V gene segments and found that the introduction of larger repertoires encoded by a κ light-chain YAC clone comprising approximately half the Vκ repertoire led to increased population of the peripheral and bone marrow B cell compartments relative to transgenic strains comprising only four Vκ genes. The relative number of mature and immature B cells in these compartments also appeared more normal in mice with larger V gene repertoires. Mendez et al. (1997) generated transgenic mice having nearly complete heavy-chain V repertoires and approximately half the κ-light-chain V repertoire, and compared them with the minilocus mice of Green et al. (1994) . This paper, and a later analysis of the same mouse strains by Green and Jakobovits (1998) , showed that V-region repertoire size had a profound effect on multiple checkpoints in B cell development, with larger repertoires capable of restoring B cell compartments to near normal levels. Despite the fact that human immunoglobulin transgenic mice express B cell receptors that are essentially hybrids of mouse and human components (e.g., human immunoglobulin, mouse Igα, Igβ, and other signaling molecules), their B cells develop and mature into what appear to be all of the normal B cell subtypes. Furthermore, the immunoglobulin transgenes undergo V(D)J joining, random nucleotide (N-region) addition, class switching, and somatic mutation to generate high-affinity MAbs to a variety of different antigens. The process of affinity maturation in these animals even recapitulates the normal pattern of somatic mutation hotspots observed in authentic human secondary repertoire antibodies (Harding and Lonberg 1995) . Fig. 3 Human immunoglobulin sequences introduced in the germ line of mice comprising endogenous Ig heavy-chain and κ-light-chain gene inactivations. The germline configuration of the human immunoglobulin λ-light chain, κ-light chain and heavy chain is depicted above bars representing those sequences used to assemble transgenes introduced into strains of mice used for generation and isolation of human sequence MAbs. A , B (Ishida et al. 2002) , C (Nicholson et al. 1999) , D (Mendez et al. 1997 ), E (Fishwild et al. 1996) , F (Green et al. 1994) , G (Lonberg et al. 1994) , H (Zou et al. 1994) There have now been multiple reports in the literature of transgenic mice having immunoglobulin repertoires comprising human heavy-and light-chain sequences in the background of disrupted endogenous heavy-and κ-light-chain loci (Fig. 3) . Several different technologies -including pronuclear microinjection and yeast protoplast fusion with ES cells -have been employed for engineering these mouse strains. The introduction of the largest fraction of the human germline repertoire has been facilitated by microcell-mediated chromosome transfer. Using this technique, Tomizuka et al. (1997) generated ES cell lines and chimeric mice containing fragments of human chromosomes 2 and 14, including the human κ-light-chain and heavy-chain loci, respectively. In addition, they generated chimeric mice that incorporated an apparently intact human chromosome 22, comprising the λ light chain locus. Germline transmission was obtained with the human κ-light-chain ES cell lines. In a subsequent report, germline transmission was obtained with a human heavy-chain ES cell line, and mice were created that expressed complete human heavy-and light-chain repertoires in a genetic background that included disruptions of the mouse heavy-and κ-light-chain loci . Completely human, high-affinity (<nanomolar) MAbs were isolated from the animals. Although both chromosome fragments could be transmitted through the germ line, the κ-light chain-containing chromosome-2 fragment was found to be less mitotically stable. The observed stability of the heavy chain-containing fragment may derive from the fortuitous location of the immunoglobulin heavy-chain locus (IgH) at the very telomere of the long arm of human chromosome 14. Because of the structure of chromosome 14, a random deletion between IgH and the centromere removed most of the nonimmunoglobulin genes leaving IgH, the centromere and both telomeres functionally intact. The resulting 10-to 20-Mb fragment minimizes crossspecies trisomy, which would presumably be selected against during cell division.
The observed stability of this fragment has now been exploited to create artificially constructed human chromosome fragments that include the entire human heavychain locus together with the entire human λ-light-chain locus (Kuroiwa et al. 2000) . Bruggemann and colleagues ) have also generated human λ-lightchain locus transgenes, using them to create transgenic mice that express partial repertoires of all three human immunoglobulin loci in the background of disrupted endogenous κ-light-chain and heavy-chain loci (Nicholson et al. 1999) .
Another transgenic mouse platform, which generates chimeric antibodies rather than fully human sequence antibodies, was developed by Rajewsky and colleagues in 1994 (Zou et al. 1994) . These mice comprise relatively precise replacements of the mouse κ and γ1 constant-region gene segments with the corresponding human gene sequences. The κ constant-region gene segment was replaced using homologous recombination in mouse ES cells. For the γ1 gene, only the secreted exons were replaced, and the engineering was accomplished in two steps using the CreloxP recombination system, also in mouse ES cells.
Transgenic Mouse-Derived Human MAbs
The scientific literature includes a large number of reports describing the characteristics of human MAbs derived from transgenic mouse platforms, and a review of this literature provides an assessment of the functionality of these platforms (Lonberg 2005) . A very diverse set of antigens have been successfully targeted with transgenic derived MAbs. These include small molecules (Ball et al. 1999; Farr et al. 2002) , pathogen-encoded proteins (Tzipori et al. 2004; Mukherjee et al. 2002; Mukherjee et al. 2002b; He et al. 2002; Greenough et al. 2005; Sheoran et al. 2005; Babcock et al. 2006; Coughlin et al. 2006; Vitale et al. 2006) , polysaccharide antigens (Chang et al. 2002; Maitta 2004) , human-secreted proteins (Mendez et al. 1997; Ishida et al. 2002; Villadsen et al. 2003; Bekker et al. 2004; Yang et al. 1999b; Huang et al. 2002; Mian et al. 2003; Ostendorf et al. 2003; Suarez et al. 2004; Parry et al. 2005; Rathanaswami et al. 2005; Burgess et al. 2006; Melnikova and Bar-Eli 2006) , cell-surface proteins (Fishwild et al. 1996; Mendez et al. 1997; Fishwild et al. 1999; Yang et al. 1999 Yang et al. , 2001 Holmes 2001; Borchmann et al. 2003; Skov et al. 2003; Teeling et al. 2004; Schuler et al. 2004; Rowinski et al. 2004; Heuck et al. 2004; Ramakrishna et al. 2004; Keler et al. 2003; Bleeker et al. 2004; Suzuki et al. 2004; Imakiire et al. 2004; Mori et al. 2004; Garambois et al. 2004; Trikha et al. 2004; Tai et al. 2005; Boll et al. 2005; Cohen et al. 2005; Kuroki et al. 2005; Sanderson et al. 2005; Tse et al. 2006; van Royen-Kerkhoff et al. 2005; Wang et al. 2005; Ma et al. 2006; Melnikova and Bar-Eli 2006; Teeling et al. 2006; Wu et al. 2006; Villadsen et al. 2007) , and human tumor-associated glycosylation variants (Nozawa et al. 2004) .
Most of the transgenic mouse-derived MAbs have binding affinities in the 0.1-10 nM range, the same affinity range typically seen for MAbs derived from wild-type mice (Ball et al. 1999; Yang et al. 1999 Yang et al. , 1999b Keler et al. 2003; Cohen et al. 2005; Burgess et al. 2006 ). This range is probably a function of the natural constraints on affinity maturation operating in vivo (Foote and Eisen 1995; Roost et al. 1995) . However, there are also examples of transgenic-derived human MAbs with picomolar and even subpicomolar affinities. Villadsen et al. (2003) described a 10 pM affinity antibody to IL-15, Wang et al. (2005) described a 4 pM affinity MAb to the insulin-like growth factor receptor, and Rathanaswami et al. (2005) reported several anti-IL-8 MAbs in the 1-10 pM range, with one MAb having a measured affinity in the 0.5-1 pM range.
Transgenic Mouse-Derived Human MAbs in the Clinic
Panitumumab and Zalutumumab
The 2006 regulatory approval in the US for panitumumab was a significant milestone for transgenic mouse-derived MAbs, and marked the first commercial validation of immunoglobulin transgenic mouse drug discovery platforms. Panitumumab binds to the epidermal growth factor receptor (EGFR) with very high affinity (K d = 5 × 10 −11 M −1 ) and blocks ligand binding (Rowinski et al. 2004; Yang et al. 1999 Yang et al. , 2001 Foon et al. 2004 ). In preclinical mouse xenograft models, it was found to be more potent than the lower affinity mouse antibody m225 (Yang et al. 1999) , the parent of the already marketed mouse/human IgG1 chimeric anti-EGFR antibody, cetuximab (Cunningham et al. 2004 ).
There has been no direct comparison of the safety and efficacy of cetuximab and panitumumab in a side-by-side clinical study. In addition, the fact that cetuximab is an IgG1 antibody and panitumumab an IgG2 antibody further complicates any attempt to compare the two drugs. However, an initial survey of the available literature suggests that the fact that panitumumab is a fully human antibody derived from a transgenic mouse may differentiate it from the chimeric cetuximab (Cohenuram and Saif 2007) . In early phase I and II trials, panitumumab was associated with a higher frequency of skin rashes than cetuximab; however, skin rashes (which are related to the mechanism of action of EGFR-targeted drugs, including small molecules, and in this case are not a product of drug immunogenicity) have been positively correlated with activity for cetuximab (Calvo and Rowinsky 2005) , and in a renal cell carcinoma trial, involving a relatively small number of patients, skin rashes correlated with longer cancer progression-free survival for panitumumab (Rowinski et al. 2004) . Later trials appear to indicate that the two molecules have similar clinical activity. In a randomized, 2-arm (231 patients in the treatment arm) phase III trial in 2nd line, chemotherapy refractory, EGFR + , metastatic colorectal carcinoma patients (Gibson et al. 2006) , there was an 8% objective response rate, with 28% of the patients having stable disease (compared with a 0% response rate and 10% stable disease in the control cohort). This compares to the clinical responses seen for cetuximab monotherapy in a 346 patient phase II trial in a similar set of refractory, EGFR + , metastatic colorectal carcinoma patients (Lenz et al. 2006) . Approximately, 12% of the cetuximab-treated patients were classified as objective responders, and 32% as stable disease. Panitumumab was dosed at 6 mg kg −1 every 2 weeks while the chimeric cetuximab was first given at a (roughly) 50% higher loading dose (400 mg m −2 ), followed by a similar weekly dose of 250 mg m −2 . The lower dosing schedule selected for panitumumab was a reflection of the longer clearance time for the fully human antibody; however, the terminal half life (7.5 days) is still shorter than is typically found for IgG molecules. This is presumably due to the large antigen sink provided by normal tissue expression of EGFR. Gibson et al. (2006) reported that no patients had detectable levels of anti-panitumumab antibodies after treatment, and that while 5% of the patients had low-grade infusion reactions, none had grade 3 or 4 reactions. In contrast, 7.5% of the cetuximab patients experienced hypersensitivity reactions with 1.7% having grade 3 or 4 reactions, despite the fact that most of those patients had been pretreated with antihistamines to prevent infusion reactions. Lenz et al. (2006) also reported that over 4% of the cetuximab-treated patients developed human antichimeric antibodies.
Because panitumumab is a human IgG2 antibody and, because IgG2 antibodies are poor mediators of Fc dependent cell killing, the activity of the drug may be a function of non-Fc mediated mechanisms. These could involve blockade of ligandinduced receptor signaling and/or altered signaling directed by MAb binding. This is consistent with the observation that the MAb is active in mouse xenograft models while a sibling human IgG2 antibody that does not block ligand binding has no activity (Yang et al. 2001 ). However, although IgG2 molecules do not show significant binding to human Fcγ RIII (CD16), they do bind to the common H131 variant of Fcγ RIIa (CD32A, Parren et al. 1992 ). This variant is also associated with clinical responses to rituximab (Weng and Levy 2003) . It is, therefore, a formal possibility that in human patients some of the activity of the panitumumab is mediated through Fcγ RIIa in H131 individuals. Gibson et al. (2006) did not report any data on the Fcγ RIIa allotype of the patients that responded to panitumumab; however, if a positive correlation between the H131 allotype and clinical responses were found it might indicate that some of the activity of the MAb is Fc mediated. Because IgG1 is a more potent mediator of Fc-dependent activity, it might then follow that a human IgG1 variant of panitumumab could have improved activity. This theory could be tested in the near future as clinical data becomes available for a second EGFR binding MAb, zalutumumab, derived from transgenic mice (Bleeker et al. 2004; Lammerts et al. 2006) . Zalutumumab is now in phase 3 testing for treatment of EGFR-positive squamous cell cancer of the head and neck. Preclinical studies of 2F8 show that like panitumumab, it is also more potent than m225 in mouse xenograft models (Bleeker et al. 2004 ). However, unlike panitumumab it is an IgG1 antibody and may function by eliciting Fc-mediated effector cell activity in addition to blocking ligand binding and normal receptor functioning. A comparison of the clinical activity of these two molecules may provide some insight into the role of Fc-receptor interaction on the efficacy and safety of these drugs.
MAbs in Phase 3 Clinical Testing
There are at least eight transgenic mouse-derived human MAbs in Phase 3 clinical trials (Table 1) . These include zalutumumab, the EGFR binding MAb discussed earlier, two different antibodies directed against CTLA-4, and one each directed against CD20 and CD4 for treatment of cancer, two neutralizing MAbs directed against TNFα and the common subunit of IL-12 and IL-23 for inflammatory indications, and an antibody directed against RANKL for bone loss.
Denosomab
Denosomab is an antibody directed against RANKL, a TNF family member that stimulates the maturation and activation of osteoclasts, which mediate bone resorption. The drug is now in phase 3 clinical trials for treatment of bone loss in postmenopausal women and in cancer patients with treatment induced bone loss or skeletal disease caused by bone metastases. A single subcutaneous dose escalation, phase 1 study in osteoporotic patients showed dose-dependent and sustained activity (up to 6 months) in blocking bone resorption, with no reported serious drugrelated adverse events (Bekker et al. 2004) . Denosomab was found to have dosedependent pharmacokinetics (PK), with a terminal half life of 32 days at the highest 3 mg kg −1 dose. A second single dose trial in patients with multiple myeloma or bone metastases from breast cancer showed decreased bone metabolism that persisted for the 84-day study follow-up period, and a mean half life of 46 days after a single 3 mg kg −1 dose (Body et al. 2006) . These studies measured bone metabolism using urine concentrations of peptide products of collagen catabolism as an indirect measure. Another trial, in postmenopausal women, looked at 3-month and 6-month repeat dosing, and also directly measured bone density (McClung et al. 2006) . Consistent with the reduction in bone metabolism seen in the single dose studies, bone density was found to be increased for the 12 months of the study, even for patients given only 60 mg of drug every 6 months. The adverse event profile for the treatment group was not significantly different from that of the placebo group, and only 2 of the 314 treated patients showed transient levels of anti-denosomab antibodies in single blood samples, which were not confirmed in later blood samples. The low incidence of measurable antidrug antibodies, the safety profile, and the very long half-life and sustained drug activity are all consistent with an antibody that is relatively nonimmunogenic. Because infrequent dosing may be very important for patient compliance for a parenterally delivered protein-based therapeutic that is directed at chronic indications such as osteoporosis, low immunogenicity could be a critical feature for the success of this product. 
Ipilimumab and CP-675206
The two transgenic mouse-derived human antibodies directed against CTLA-4, ipilimumab, and CP-675206, also do not appear to elicit strong patient antidrug antibody responses, despite the fact that the mechanism of action for these drugs results in a very potent up-modulation of patient immune responses. CTLA-4 is a negative T cell signaling molecule that binds to the two ligands CD80 and CD86, both of which are also recognized by the positive T cell signaling molecule CD28 (Korman et al. 2006) . Ipilimumab (Keler et al. 2003 ) is a human IgG1 antibody, while CP-675206 (Ribas et al. 2005 ) is an IgG2 antibody. Both molecules bind to human CTLA-4 so as to block ligand binding and antagonize CTLA-4 signaling, resulting in the activation of certain T cell responses. Experiments with hamster MAbs that block mouse CTLA-4 show that the resulting enhanced immune responses can mediate tumor rejection in syngeneic mouse tumor models (Leach et al. 1996) . Preclinical experiments in cynomolgus monkey models demonstrated that ipilimumab could stimulate humoral immune responses to coadministered vaccines (Keler et al. 2003) . Clinical data in cancer patients has been reported for both ipilimumab (Phan et al. 2003; Hodi et al. 2003; Ribas et al. 2004; Attia et al. 2005; Blansfield et al. 2005; Maker et al. 2005 , 2005b Sanderson et al. 2005 Beck et al. 2006; Thompson et al. 2006 ) and CP-675206 (Ribas et al. 2004 , 2005 , Reuben et al. 2006 . Objective and durable antitumor responses were observed for both drugs. Rosenberg and colleagues conducted a trial in patients with metastatic melanoma who were treated with ipilimumab at 3 mg kg −1 every 3 weeks for up to six cycles or were given a loading dose of ipilimumab at 3 mg kg −1 followed by 1 mg kg −1 every 3 weeks for up to six cycles. All patients were administered a subcutaneous gp100 peptide vaccine . The overall objective response rate for the 56 patients in the combined cohorts was 13%, with ongoing complete and partial responses reported at 25, 26, 30, 31, and 34 months. A follow-up paper by this group included additional metastatic melanoma patients treated with and without the vaccine, some receiving ipilimumab doses as high as 9 mg kg −1 , together with 61 renal cell carcinoma patients treated with ipilimumab at up to 3 mg kg −1 (Beck et al. 2006) . The overall objective response rate for the 198 patients in this report was 14%. This group also combined ipilimumab and high dose IL-2 in metastatic melanoma patients and reported a 22% objective response rate in patients administered ipilimumab at 3 mg kg −1 . In a phase 1 single dose, monotherapy, dose escalation trial of CP-675206 in metastatic melanoma, with patients receiving doses as high as 15 mg kg −1 , the authors reported a 10% objective response rate (Ribas et al. 2005) , although one of the four responders had also received ipilimumab (Ribas et al. 2004 ). The serious adverse events reported for both ipilimumab and CP-675206 comprise a spectrum of immune-related inflammatory responses including rash, enterocolitis, and hypophysitis (Jaber et al. 2006; Blansfield et al. 2005; Ribas et al. 2005; Beck et al. 2006) . However, because the mechanism of action of CTLA-4 blocking MAbs involves the activation of immune responses, these have been considered as target-related toxicities, and have in fact correlated with clinical responses (Beck et al. 2006 , Reuben et al. 2006 . Beck et al. (2006) reported 36% and 35% objective response rates for melanoma and renal cell cancer patients having enterocolitis, with response rates of only 11% and 2% for patients without enterocolitis. The inflammatory adverse events have been reported to respond to medical management, which may include corticosteroids. Interestingly, corticosteroid treatment does not appear to abrogate objective tumor responses Beck et al. 2006) . Despite the observed up-regulation of immune responses in patients treated with these two MAbs, the drugs themselves do not appear to be readily recognized and cleared by the human immune system. A terminal half-life of 22 days was reported for CP-675206 (Ribas 2005) , and 1-month postdosing serum trough levels of 10 µg ml −1 ipilimumab were reported after 5 months of repeated monthly dosing at 3 mg kg −1 (Sanderson et al. 2005) . Sanderson et al. (2005) also reported that these repeatedly dosed patients did not develop a measurable antibody response to ipilimumab. These data are consistent with the data from preclinical studies that showed no evidence of monkey anti-human antibody formation in cynomolgus macaques dosed five times over 140 days (Keler et al. 2003) , despite the fact that the MAb upregulated the monkey humoral immune responses to coadministered vaccines. There was no sign of immune clearance by monkey antihuman antibodies, with drug titers never falling below 20 µg ml −1 over the course of the 5-month study.
CNTO 1275 and Golimumab
Another transgenic-derived human MAb in phase 3 development is CNTO 1275, which is directed against the common p40 subunit shared by IL-12 and IL-23. Results have been reported from a phase 1 trial in multiple sclerosis (Kasper et al. 2006) and from phase 1 and 2 trials in psoriasis (Kauffman et al. 2004 , Toichi et al. 2006 , Krueger et al. 2007 ). In the phase 1 psoriasis trial, the drug showed sustained activity over 16 weeks of follow-up with a single i.v. administration, with 67% of the patients achieving at least a 75% improvement (assessed by the Psoriasis Area and Severity Index). There were no treatment-related serious adverse events, and no infusion reactions. Antidrug antibodies were detected in 1 of 18 patients; however, presence of drug in the serum because of the very long terminal half life, 19-27 days, precluded accurate assessment in most of the patients. A similar 20-31 day terminal half-life was observed in the multiple sclerosis trial where the drug was given by subcutaneous administration. One of the 16 treated patients developed a detectable antidrug response; however, as with the psoriasis trial, the persistence of the drug in the serum made it difficult to accurately measure antidrug antibodies. In the phase 2 psoriasis trial, 237 patients received the drug for up to four weekly 90 mg subcutaneous doses. Antidrug antibodies were detected once or more in the 52 weeks of monitoring in 12 (4%) of the treated patients. However, the measured antibody response did not correlate with injection site reactions, which occurred at the same 2% frequency in both placebo and drug-treated cohorts. Patients given only a single subcutaneous dose, at either 45 or 90 mg, showed sustained disease-modifying responses for over 6 months following treatment. Together with the observed sustained clinical benefit, the approximately 20-30 day terminal half-life of CNTO 1275 appears to indicate that it does not elicit a strong drug-clearing antibody response. As further clinical data are reported, it will be interesting to compare the immunogenicity, PK, safety, and efficacy of the transgenic mouse-derived CNTO 1275 to the phage display derived ABT-874, which is also directed against the common p40 subunit of IL12 and IL-23 (Mannon et al. 2004 , Fuss et al. 2006 . The phage display antibody also showed some signs of immunogenicity, with antidrug antibodies detectable in 3 of 63 patients, and 2 of those patients showing evidence of early clearance of the drug from the serum (Mannon et al. 2004) ; however, because patients received up to 7 weekly doses of the drug, it is difficult to compare the data to that reported for CNTO 1275. The terminal half life of ABT-874 was not reported.
Data should also soon be available to compare a second pair of antibodies directed against a shared target but derived from the competing transgenic mouse and phage display technology platforms. Both golimumab, a human sequence antibody from transgenic mice is now in phase 3 clinical testing in rheumatoid arthritis, and adalimumab, a phage display derived antibody currently approved for the same indication, are high affinity TNFα blocking MAbs (Weinblatt et al. 2003) . Both are also IgG1 molecules formulated for subcutaneous administration. This comparison may be of particular interest because adalimumab has been reported to elicit antidrug antibodies at a high frequency, despite the fact that it was genetically engineered from a lead molecule originally isolated from a phage display library constructed from human immunoglobulin sequences. The formation of these antidrug antibodies correlated with adverse events and reduced efficacy in a study of 15 rheumatoid arthritis patients (Bender et al. 2007 ). Another approved TNFα blocking antibody, infliximab, is a chimeric mouse-human antibody that also elicits a strong antidrug antibody response, which correlates with infusion reactions and reduced efficacy (Baert et al. 2003) . Data from a third MAb derived from an alternative technology may provide some insight into the relative importance of factors such as drug target, patient population, and intrinsic immunogenicity on the efficacy and safety of antibody-based therapeutics.
Zanolimumab
Zanolimumab is a transgenic mouse-derived human antibody directed against the T cell antigen CD4 (Fishwild et al. 1999) . Results from an 85 patient, placebocontrolled, phase 2 trial in psoriasis have been reported (Skov et al. 2003) , and the drug is now in phase 3 clinical testing in cutaneous T cell lymphoma. In the published psoriasis study, there was an observed dose-dependent decrease in circulating CD4 + cells, particularly in the CD45RO + memory T cell population. This may translate to efficacy in the cancer setting where the drug is currently being developed (Villadsen et al. 2007 ). The drug was well tolerated with one likely drug-related serious adverse event, a rash appearing after the second dose at 160 mg. No patients developed antidrug antibodies. In the published preclinical study (Fishwild et al. 1999) , the antibody was found to be nonimmunogenic in chimpanzees; however, it did induce a blocking antibody response in a majority of the dosed cynomolgus monkeys (demonstrating that primate models may, in some cases, overestimate immunogenicity).
Ofatumumab
Ofatumumab (Teeling et al. 2004 ), a transgenic mouse-derived antibody directed at the B cell surface antigen CD20, is also in phase 3 clinical development. Although this antibody shares the same target as the mouse-human chimeric MAb rituximab, which is currently approved for treatment of non-Hodgkin's lymphoma (NHL) and rheumatoid arthritis (Coiffier et al. 1998 , it recognizes a distinct epitope and may, as a result, have a different mechanism of action (Teeling et al. 2006 ). Rituximab appears to recognize only one of the two extracellular loops of CD20, while the ofatumumab epitope comprises residues from both loops and the antibody is a more potent mediator of complement-dependent cytotoxicity in vitro than rituximab. This difference in potency is more pronounced at lower antigen density, and may translate into greater activity in low CD20 expressing lymphomas such as chronic lymphocytic leukemia (CLL), where the drug is currently being tested in phase 3 clinical trials. Because of the potential difference in mechanism of action and activity between ofatumumab and rituximab, a comparison of their relative safety and efficacy profiles may not be as useful for evaluating the potential of human vs. chimeric antibodies; however, the process for selecting ofatumumab as the lead clinical candidate (Teeling et al. 2004 , Teeling et al. 2006 ) does highlight an important advantage of the transgenic mouse platform over other antibody drug discovery platforms. Unlike antibody engineering technologies for making low immunogenicity MAbs, where an early lead candidate is then modified or optimized in vitro to reduce immunogenicity, with the transgenic mouse platforms, the process of lead optimization is bypassed, making it possible to test each potential lead candidate in a series of increasingly sophisticated in vitro and in vivo assays in essentially the same molecular form as it will eventually be used in humans. Resources that would otherwise be devoted to optimization of a small number of lead hits can be devoted to better characterization of a larger number of lead candidates comprising a wider variety of functional properties.
MAbs in Phase 1 and 2 Clinical Testing
The available published scientific literature does not include the same level of detailed data on drug tolerability, PK, and efficacy for molecules that have not yet entered phase 3 clinical testing; however, published abstracts from scientific meetings and discussions in review articles does provide some information. A transgenic mouse-derived anti-CD30 MAb, MDX-060 (Borchmann et al. 2003; Heuck et al. 2004; Boll et al. 2005) , has been tested in Hodgkin's lymphoma and anaplastic large cell lymphoma patients Borchmann et al. 2005; Klimm et al. 2005) . Fifty-six patients were reported to have been treated with up to 15 mg kg −1 every week for 4 weeks without significant infusion reactions. The preliminary results were interpreted to indicate that the drug was well tolerated and had clinical activity. Preclinical results have also been published for additional transgenic-derived MAbs now in clinical testing. These include antibodies directed against IL-15 (Villadsen et al. 2003) , PSMA (Holmes 2001) , Clostridium difficile toxins A and B (Babcock et al. 2006) , CD40 (Tai et al. 2005) , anthrax protective antigen (Vitale et al. 2006) , hepatocyte growth factor (Burgess et al. 2006) , melanoma antigen glycoprotein NMB (Tse et al. 2006 ), insulin-like growth factor receptor (Cohen et al. 2005) , and α v integrins (Trikha et al. 2004; Martin et al. 2005) .
Conclusions
Transgenic mice that express human antibody repertoires have proven to be useful for generating high-affinity human sequence MAbs against a wide variety of potential drug targets. The clinical experience with a variety of transgenic mouse derived fully human antibodies in human patients shows promising efficacy and safety profiles for several of these molecules. Furthermore, the overall experience to date is that the technology has succeeded in delivering human MAbs that demonstrate relatively low immunogenicity and have relatively long in vivo half lives. Twelve years after the first publications describing transgenic mice having disrupted endogenous immunoglobulin loci and expressing human heavy and light chain repertoires, the US regulatory approval of panitumumab provides commercial validation for this drug discovery platform. In addition, the variety and very large number of different clinical and preclinical programs involving human MAbs from transgenic mice suggest that the technology will continue to contribute new therapeutic drugs.
